 |
Hanmi Pharmaceutical |
[Alpha Biz= Reporter Kim Jisun] Hanmi Pharmaceutical has initiated an internal investigation into its subsidiary, Beijing Hanmi Pharmaceutical, following allegations of favoritism towards the eldest son of the founder, Im Jong-yoon, director of Hanmi Science. This move comes in response to recent claims that the COREE Group, effectively owned by Im Jong-yoon, was favored in business dealings.
According to industry sources on the 7th, Hanmi Pharmaceutical has commenced an official audit through its audit committee to examine suspicions of unfair internal transactions involving Beijing Hanmi Pharmaceutical. The investigation will focus on the alleged preferential treatment between COREE Group's subsidiary, Runmeikang, and Beijing Hanmi Pharmaceutical, as well as non-transparent contracts. President Park Jae-hyun of Hanmi Pharmaceutical reportedly communicated to the executives on the 5th that the issue is being taken seriously and that appropriate measures would be taken.
Runmeikang is responsible for distributing pharmaceuticals produced by Beijing Hanmi Pharmaceutical within China, raising concerns about potential unfair internal transactions.
A representative of Hanmi Pharmaceutical stated, "We will confirm that we operate with a transparent and advanced management system to dispel any doubts and plan to improve any processes that may have issues."
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
